endpoint extends IRT accessibility across clinical development portfolio
According to the global interactive response technology (IRT) company, the update extends IRT accessibility to investigator-initiated trials (IIT) and early-phase, late-phase, and compassionate use studies.
“Aside from some additional features and tools available to our users, the main enhancement we’ve made is enabling our clients to manage their drug supply above and beyond at the protocol level, if this is of interest to them,” Chuck Harris, CEO, endpoint Clinical, told Outsourcing-Pharma.com
In keeping with the company’s approach to innovation, Harris said the product enhancement is directly related to current client requests – and the company’s impression on where the market is headed.
“IRT is our core offering and expertise, so we feel we are best equipped with enhancing our IRT products and services on our own versus through acquisitions,” added Harris, who explained that the announcement is “just one of many exciting product enhancements that will be coming from endpoint throughout the next year.”
endpoint initially introduced its clinical supply management tool, DRIVE, in conjunction with DIA 2016 in June of last year.